A Phase 3 Study of AGA111 in Patients With Degenerative Disc Disease Undergoing Lumbar Interbody Fusion

Summary

The primary objective of the study is to assess the overall efficacy of a single intervertebral local administration of AGA111 in patients with degenerative disc disease undergoing lumbar interbody fusion.

Timeline

Start

2023-12-08

Primary completion

2025-11-28

Completion

2026-06-12

Outcome

Outcome not reported

Stopped (Business): “Sponsor's strategic decision not related to safety concerns.”

Drugs

Indications